Literature DB >> 5848663

Suppression of the tuberculin response in malignant disease.

L E Hughes, W D Mackay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1965        PMID： 5848663      PMCID： PMC1846760          DOI： 10.1136/bmj.2.5474.1346

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  16 in total

Review 1.  EFFECTS OF CARCINOGENS ON IMMUNE PROCESSES.

Authors:  M C BERENBAUM
Journal:  Br Med Bull       Date:  1964-05       Impact factor: 4.291

2.  TOLERANCE AGENT IN HUMAN CANCER.

Authors:  J B GRAHAM; R M GRAHAM
Journal:  Surg Gynecol Obstet       Date:  1964-06

3.  DECLINING TUBERCULIN SENSITIVITY WITH ADVANCING AGE.

Authors:  R N JOHNSTON; R T RITCHIE; I H MURRAY
Journal:  Br Med J       Date:  1963-09-21

4.  PRELIMINARY OBSERVATIONS ON TREATMENT OF ADVANCED CANCER BY INJECTION OF ALLOGENEIC SPLEEN CELLS.

Authors:  M F WOODRUFF; B NOLAN
Journal:  Lancet       Date:  1963-08-31       Impact factor: 79.321

5.  CIRCULATING ANTIBODY RESPONSE IN MALIGNANT DISEASE.

Authors:  B LYTTON; L E HUGHES; A J FULTHORPE
Journal:  Lancet       Date:  1964-01-11       Impact factor: 79.321

6.  A comparative study of the incidence of anergy in patients with carcinoma, leukemia, hodgkin's disease and other lymphomas.

Authors:  D LAMB; F PILNEY; W D KELLY; R A GOOD
Journal:  J Immunol       Date:  1962-10       Impact factor: 5.422

7.  Inhibition of Mantoux reaction by direct suggestion under hypnosis.

Authors:  S BLACK; J H HUMPHREY; J S NIVEN
Journal:  Br Med J       Date:  1963-06-22

8.  The effect of cortisone upon the reaction of the skin to tuberculin in tuberculosis and in sarcoidosis.

Authors:  K M CITRON; J G SCADDING
Journal:  Q J Med       Date:  1957-07

9.  Mumps virus antihaemagglutinin values in cancer patients.

Authors:  J LOGAN
Journal:  N Z Med J       Date:  1953-10

10.  Immunological deficiency diseases. Agammaglobulinemia, hypogammaglobulinemia, Hodgkin's disease and sarcoidosis.

Authors:  R A GOOD; W D KELLY; J ROTSTEIN; R L VARCO
Journal:  Prog Allergy       Date:  1962
View more
  21 in total

1.  Frontiers in inflammatory bowel disease. The proceedings of a conference sponsored by the McReynolds Foundation. Part II.

Authors:  R G Shorter; D A Shephard
Journal:  Am J Dig Dis       Date:  1975-07

2.  Letter: Prognostic indications in cancer.

Authors:  A R Turnbull; C E Connolly; B M Jones
Journal:  Br Med J       Date:  1975-06-14

3.  The effects of surgery on lymphocyte transformation in patients with cancer.

Authors:  S M Watkins
Journal:  Clin Exp Immunol       Date:  1973-05       Impact factor: 4.330

4.  Human resistance to tumours.

Authors:  G H Fairley
Journal:  Proc R Soc Med       Date:  1967-11-01

5.  Quantitative dinitrochlorobenzene contact sensitization in a normal population.

Authors:  W J Catalona; P T Taylor; P B Chretien
Journal:  Clin Exp Immunol       Date:  1972-11       Impact factor: 4.330

6.  Immunobiology of operable breast cancer: an assessment of biologic risk by immunoparameters.

Authors:  H J Wanebo; P P Rosen; T Thaler; J A Urban; H F Oettgen
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

Review 7.  Tumour immunology and the gut.

Authors:  K C Calman
Journal:  Gut       Date:  1975-06       Impact factor: 23.059

8.  A quantitative and qualitative study of blood monocytes in patients with bronchogenic carcinoma.

Authors:  H Nielsen; J Bennedsen; S O Larsen; P Dombernowsky; K Viskum
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

9.  Immunotherapy of Lewis lung carcinoma with hydrosoluble peptidoglycan monomer (PGM).

Authors:  G Sava; T Giraldi; J Tomasić; I Hrsak
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Phytohaemagglutinin-induced lymphocyte transformation in patients before and after resection of large intestinal cancer.

Authors:  M B McIllmurray; M Gray; M J Langman
Journal:  Gut       Date:  1973-07       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.